We thank Dr. Stanton and colleagues for their great work evaluating the clinical outcomes of apixaban in patients with severe renal dysfunction, ultimately concluding apixaban is a reasonable alternative to warfarin.(1) One question that clinicians should ask before applying this conclusion to clinical practice is what dose of apixaban should be used? The authors note that patients were primarily receiving apixaban 2.5 mg twice/day but gave no further breakdown based upon indication or level of renal dysfunction. The current FDA labeled dose of apixaban for hemodialysis patients (26.1% of the study population), is 5 mg twice/day (2.5mg twice/day if age ≥80 years or body weight ≤60 kg) for non-valvular atrial fibrillation (NVAF).(1,2) This article is protected by copyright. All rights reserved.
Pharmacology, Toxicology and Pharmaceutical Science
6
27%
Medicine and Dentistry
5
23%
Unknown
11
50%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 July 2017.
All research outputs
#22,322,468
of 34,372,222 outputs
Outputs from Pharmacotherapy
#2,554
of 3,217 outputs
Outputs of similar age
#209,894
of 354,230 outputs
Outputs of similar age from Pharmacotherapy
#22
of 48 outputs
Altmetric has tracked 34,372,222 research outputs across all sources so far. This one is in the 33rd percentile – i.e., 33% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,217 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one is in the 19th percentile – i.e., 19% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 354,230 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
